CARLSBAD, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Company plans to launch its advanced joint supplement, designed to potentially reduce joint pain associated with osteoarthritis, in Q3 2018.
The initial launch will be geared towards existing Lifeline Skin Care customers, who represent the target demographic and who have been loyal to the brand. The Company will evaluate the results of the soft launch and determine which additional sales channels (i.e. retail, doctors’ offices) it plans to pursue outside of the online space.
"The research our scientific team recently published in the Journal of Tissue Engineering and Regenerative Medicine has illustrated that by combining the right ingredients, mesenchymal stem cells possess the remarkable potential to repair human cartilage tissue," commented Russell Kern, PhD, ISCO's Executive Vice President and Chief Scientific Officer. “Our scientists have developed a scalable, unique joint supplement designed to potentially reduce joint wear-and-tear, alleviate muscle cramps, and relieve stressed tendons,” he continued.
According to the Centers for Disease Control and Prevention, osteoarthritis is the most common form of degenerative joint disease and affects roughly 630 million people worldwide. With this, Technavio analysts are predicting that the global bone and joint supplements market will reach $3.3 billion by the end of 2023.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ( www.lifelinecelltech.com ),and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( www.lifelineskincare.com ). More information is available at www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, clinical studies expectations (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation Dr. Russell Kern EVP, Chief Scientific Officer (760) 940-6383 ir@intlstemcell.com
